Aug 2, 2019

Visiting Professors: Lung Cancer Edition — Part 1: Our discussion with Drs Levy and Lobins highlights the following topics as well as cases from Dr Lobins’s practice:

• Case: A man in his early 60s, a current smoker, with metastatic lung adenocarcinoma and a PD-L1 tumor proportion score (TPS) of 80% experiences a dramatic response to first-line pembrolizumab but a recurrence of small lymphocytic lymphoma (SLL) during therapy (00:00)
• Activity and tolerability of immune checkpoint inhibitors alone or with chemotherapy as first-line therapy in patients with metastatic non-small cell lung cancer (NSCLC) (02:30)
• Duration of therapy with immune checkpoint inhibitors (05:28)
• Perspectives on the effects of recent advances in the management of lung cancer on the practice of oncology (09:16)
• Potential correlation between recurrence of chronic lymphocytic leukemia or SLL and treatment with anti-PD-1/PD-L1 antibodies (11:02)
• Case: A woman in her late 50s with a history of autoimmune uveitis is diagnosed with NSCLC and multiple metastases in the brain (13:46)
• Side effects associated with whole-brain radiation therapy (14:55)
• Use of immune checkpoint inhibitors for patients with preexisting autoimmune disorders (17:45)
• Therapeutic options for patients with metastatic NSCLC in the second-line setting (22:05)
• Results of the Phase III REVEL trial investigating ramucirumab with docetaxel as second-line therapy for patients with metastatic NSCLC (24:16)
• Activity of ramucirumab in patients with squamous cell NSCLC and those with prior exposure to bevacizumab (25:45)
• Side effects and tolerability of ramucirumab and bevacizumab (26:46)
• Case: A man in his early 50s, a current smoker, with metastatic lung adenocarcinoma and a BRAF non-V600E tumor mutation receives first-line carboplatin/pemetrexed/pembrolizumab (29:19)
• Hemoptysis as a presenting symptom of lung cancer (30:28)
• Clinical care of patients with metastatic NSCLC and no identified targetable tumor mutations (32:58)
• Novel agents and approaches under investigation for lung cancer (36:11)
• Mechanisms of resistance to immunotherapy (39:15)
• Monitoring for immune-related adverse events in patients receiving immune checkpoint inhibitors (41:31)
• Case: A woman in her mid-50s with large cell neuroendocrine carcinoma of the lung and a solitary metastasis in the brain (43:20)
• Perspective on the management of oligometastatic disease (45:55)
• Therapeutic options for patients with metastatic large cell neuroendocrine carcinoma of the lung (48:10)
• Management of metastatic small cell lung cancer in the second-line setting (51:07)
• Case: A man in his early 80s with severe pulmonary fibrosis is diagnosed with metastatic NSCLC (54:40)
• Challenges in the management of pulmonary fibrosis in elderly patients with lung cancer (58:22)
• Biologic rationale for and emerging data with immune checkpoint inhibitors in combination with anti-angiogenic agents (1:01:13)
• Benefits and challenges of integrating early palliative care into the management of metastatic lung cancer (1:03:55)
• Case: A man in his late 60s with metastatic NSCLC with KRAS and p53 tumor mutations experiences disease progression on multiple lines of therapy (1:06:27)
• Therapeutic approach for patients with metastatic NSCLC in the late-line setting (1:08:26)
• Case: A woman in her early 20s initially diagnosed with unresectable Stage III NSCLC with mutations in ROS1 and p53 develops metastatic disease (1:13:22)
• Activity and tolerability of crizotinib and lorlatinib in patients with metastatic NSCLC and ROS1 tumor mutations (1:15:37)
• Sequencing therapies for patients with metastatic NSCLC and ROS1 tumor mutations (1:18:23)

CME information and select publications